Document resource
The incorporation of immune checkpoint inhibitors (ICIs) has transformed the management of advanced non-small cell lung cancer, establishing immunotherapy as a cornerstone of treatment. However, the therapeutic benefit remains heterogeneous, and identifying factors that influence response is essential to advancing precision oncology. Among these factors, sex is a biologically plausible yet incompletely understood determinant.